Itgam Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
ITGAM encodes integrin alpha M (CD11b), the alpha chain of the heterodimeric receptor alphaMbeta2 (CR3/Mac-1) with ITGB2. In the CNS this receptor is central to myeloid adhesion, complement-opsonin recognition, phagocytosis, and inflammatory signal integration in microglia.[1][2]
| Gene Symbol | ITGAM |
|---|---|
| Full Name | Integrin Subunit Alpha M (CD11b) |
| Chromosomal Location | 16p11.2 |
| NCBI Gene ID | 3684 |
| Ensembl ID | ENSG00000169896 |
| UniProt ID | P11215 |
| Major Complex | CR3 / Mac-1 (CD11b-CD18) |
CD11b/CD18 is a multifunctional immune receptor that binds complement fragment iC3b, ICAM-family ligands, fibrinogen, and damage-associated molecular patterns. In neurodegeneration-relevant contexts, ITGAM supports:
Because complement system activation is prominent in AD, PD, and ALS tissue, ITGAM is a mechanistically important bridge between complement deposition and effector microglial responses.[2:1][4]
In Alzheimer's disease, CD11b-positive microglia accumulate near plaques and neuritic pathology. Complement tagging and CR3-dependent uptake can help clear cellular debris, yet persistent activation may also enhance synapse loss and inflammatory injury if not tightly regulated.[2:2][4:1][5]
This duality makes ITGAM relevant to therapeutic design: overly suppressing CR3 can impair clearance, while unchecked activation may amplify chronic neuroinflammation and circuit dysfunction.
In Parkinson's disease, CD11b upregulation is consistently reported in activated microglia within nigrostriatal regions.[6] Engagement of ITGAM-dependent signaling alongside alpha-synuclein-triggered innate immune pathways contributes to cytokine release and oxidative stress pressure on dopaminergic neurons.[6:1][7]
In amyotrophic lateral sclerosis, CD11b-positive myeloid responses track with disease progression in spinal cord and motor pathways.[8] Similar ITGAM-associated signatures are observed in other disorders where neuroinflammation and complement dysregulation are major pathogenic axes.
ITGAM sits at the interface of immune recognition and tissue remodeling:
This connects ITGAM directly to complement-mediated-synapse-loss, innate-immune-signaling-ad, and selective-neuronal-vulnerability.
Potential translational strategies include:
Because ITGAM is broadly expressed across myeloid populations, CNS-targeted approaches should account for peripheral immune effects and stage-dependent biology.
Itgam Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Itgam Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Outside neurodegeneration, ITGAM coding variants are well studied in systemic autoimmune disease, showing that modest shifts in CR3 function can materially alter immune tone.[1:2][3:1] For CNS applications, this supports a precision-medicine view: genotype, disease stage, and inflammatory milieu likely determine whether CR3-axis modulation is beneficial or detrimental.
In translational neurodegeneration studies, CD11b is best interpreted as part of a panel that includes complement activation markers, microglial state programs, and neuronal injury biomarkers.[2:4][4:3][9:2] This multi-marker approach is important because high CD11b signal can reflect effective debris clearance, maladaptive synapse stripping, or mixed states coexisting in the same tissue region.
For Alzheimer's disease, a plausible intervention strategy is staged modulation: preserve early CR3-dependent plaque compaction/clearance while limiting chronic complement-driven synaptic injury in later disease phases.[4:4][5:2]
For Parkinson's disease, ITGAM-targeted approaches may need to be paired with therapies that reduce alpha-synuclein burden and oxidative injury to avoid isolated immune suppression without substrate control.[6:3][7:1][8:1]
Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit Rev Immunol. 2000. ↩︎ ↩︎ ↩︎
Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Immunol. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Solovjov DA, Pluskota E, Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. Front Immunol. 2015. ↩︎ ↩︎
Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007. ↩︎ ↩︎ ↩︎
Tansey MG, Romero-Ramos M. [Immune system responses in Parkinson's disease: early and dynamic](https://doi.org/10.1016/S1474-4422(19). Lancet Neurol. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Pajares M, Rojo AI, Manda G, Bosca L, Cuadrado A. Inflammation in Parkinson's disease: mechanisms and therapeutic implications. Cell Signal. 2019. ↩︎ ↩︎
Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D'Ambrosi N. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci. 2017. ↩︎ ↩︎
Deczkowska A, Keren-Shaul H, Weiner A, et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell. 2018. ↩︎ ↩︎ ↩︎